SAPRIS-SERO est une étude qui vise à estimer la séroprévalence de l’infection par le SRAS-CoV-2 dans les cohortes épidémiologiques Constances, E3-E4N, NutriNet-Santé et Elfe-Epipage2 en France.

SAAS, Andorra  


Rejoignez l’étude COVonco et contribuez a comprendre mieux l’impact de la COVID-19 dans l’oncologie.



Le projet EpiCOV vise à fournir une cartographie globale et scientifiquement fiable du statut immunitaire de la population en France à travers des tests sérologiques et des questionnaires.

Catalunya Central Health region, Spain  

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

Institut Català de la Salut, Spain  

COVID-19 immunity in healthcare professionals

Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients


Mass SARS-CoV-2 Serological Screening in Andorra

This study aims to estimate the prevalence of antibodies against SARS-CoV-2 and help improve the prediction of infectious diseases and increase biosecurity in the Principality of Andorra.

Technische Universität München, Germany  


Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.

Catalonia, Spain  


The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.

Assistance Publique des Hopitaux de Paris, France  

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.

Imperial College London et al., United Kingdom  

REACT-2.5: National seroprevalence study of SARS-CoV-2 antibodies using LFIAs

This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.

Imperial College London et al., United Kingdom  

REACT-2.4: Usability and validity of LFIA self-testing in key workers

This study assesses whether LFIAs should be used as a self-administered test among key workers or whether better performance is obtained if they attend a central clinic facility, e.g. for blood draw.

Imperial College London et al., United Kingdom  

REACT-2.3: Acceptability and Usability of In-home Self-testing for SARS-CoV-2

This COVID-19 study aims to evaluate the acceptability and usability of in-home self-testing for SARS-CoV-2 antibodies.